These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32096064)

  • 1. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.
    Gargiulo G; Esposito G; Cirillo P; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Avvedimento M; Tebaldi M; Wahl A; Hunziker L; Billinger M; Heg D; Windecker S; Valgimigli M
    J Cardiovasc Transl Res; 2021 Feb; 14(1):110-119. PubMed ID: 32096064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
    Rollini F; Franchi F; Hu J; Kureti M; Aggarwal N; Durairaj A; Park Y; Seawell M; Cox-Alomar P; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    J Am Coll Cardiol; 2016 May; 67(17):1994-2004. PubMed ID: 27012781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
    Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
    Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.
    Silverio A; Bellino M; Scudiero F; Attisano T; Baldi C; Catalano A; Centore M; Cesaro A; Di Maio M; Esposito L; Granata G; Maiellaro F; Muraca I; Musumeci G; Parodi G; Personeni D; Valenti R; Vecchione C; Calabrò P; Galasso G
    J Thromb Thrombolysis; 2024 Jun; 57(5):757-766. PubMed ID: 38615155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
    Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
    Bulluck H; Chong JH; Bryant J; Annathurai A; Chai P; Chan M; Chawla A; Chin CY; Chung YC; Gao F; Ho HH; Ho AFW; Hoe J; Imran SS; Lee CH; Lim B; Lim ST; Lim SH; Liew BW; Zhan Yun PL; Ong MEH; Paradies V; Pung XM; Tay JCK; Teo L; Ting BP; Wong A; Wong E; Watson T; Chan MY; Keong YK; Tan JWC; Hausenloy DJ;
    Circulation; 2024 Jul; 150(2):91-101. PubMed ID: 38742915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
    Gargiulo G; Nagler M; Valgimigli M
    Circulation; 2021 Mar; 143(13):e797-e798. PubMed ID: 33779272
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
    Angiolillo DJ; Bhatt DL; Stone GW
    Circulation; 2021 Mar; 143(13):e795-e796. PubMed ID: 33779271
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Vogel RF; Delewi R; Angiolillo DJ; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Krucoff MW; van Mieghem NM; Smits PC; Vlachojannis GJ
    JACC Cardiovasc Interv; 2021 Jun; 14(12):1323-1333. PubMed ID: 34167672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
    Vivas D; Jiménez JJ; Martín-Asenjo R; Bernardo E; Ortega-Pozzi MA; Gómez-Polo JC; Moreno G; Vilacosta I; Pérez-Villacastín J; Fernández-Ortiz A
    J Thromb Thrombolysis; 2023 Feb; 55(2):203-210. PubMed ID: 36480147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.